Cargando…
Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU-0063794 and KU-0068650) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity
Mammalian target of rapamycin (mTOR) is essential in controlling several cellular functions. This pathway is dysregulated in keloid disease (KD). KD is a common fibroproliferative dermal lesion with an ill-defined treatment strategy. KD demonstrates excessive matrix deposition, angiogenesis, and inf...
Autores principales: | Syed, Farhatullah, Sanganee, Hitesh J, Bahl, Ashwani, Bayat, Ardeshir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631609/ https://www.ncbi.nlm.nih.gov/pubmed/23303455 http://dx.doi.org/10.1038/jid.2012.483 |
Ejemplares similares
-
A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
por: Zhang, Hao, et al.
Publicado: (2013) -
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009) -
Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
por: Jeon, Ye-Won, et al.
Publicado: (2022) -
Site-Specific Keloid Fibroblasts Alter the Behaviour of Normal Skin and Normal Scar Fibroblasts through Paracrine Signalling
por: Ashcroft, Kevin J., et al.
Publicado: (2013) -
Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy
por: Lee, Sang Chul, et al.
Publicado: (2018)